AvevoRx Named Second Fastest-Growing Company in Triad Business Journal Fast 50

GREENSBORO, N.C., Oct. 2, 2026 /CourierPR/ -- AvevoRx, a national, independent provider of specialty infusion pharmacy services, has been named the second-fastest-growing company in the 2026 Triad Business Journal Fast 50 Awards, marking its third consecutive appearance in the top 50. This recognition follows the company's No. 2 ranking in 2024 and No. 3 ranking in 2025. The Greensboro-headquartered company has seen significant growth since its founding in 2021, expanding its national specialty infusion pharmacy platform through strategic acquisitions, new market entry, and investments in clinical and patient-support programs.

AvevoRx's rapid growth has enabled it to serve approximately 97 percent of the U.S. population. The company has expanded its pharmacy infrastructure in key growth markets, including the addition of advanced clean-room pharmacy operations in Metro Atlanta and Austin, Texas. This expansion supports patients across the Southeast, Texas, and the broader Southwest. Additionally, AvevoRx has established a major presence in the Northeast through the acquisition of Long Island-based Sunrise Rx, which now serves New York, New Jersey, Connecticut, and New Hampshire.

The company has also focused on broadening patient access through payer relationships. AvevoRx has continued to expand managed-care and pharmacy-benefit relationships, which have extended coverage to more than 18 million additional covered lives. This strategy aims to increase patient access and enter new markets with payer alignment already in place.

AvevoRx has invested in specialized patient programs, including the expansion of its national Alpha-1 Advocacy Program and the launch of a national nutrition education and engagement initiative for patients with complex gastrointestinal disorders who rely on home parenteral nutrition. These programs are designed to enhance patient education, physician engagement, and advocacy services.

The company has also expanded its clinical capacity and high-touch care by building its national nursing capabilities to support complex home infusion therapies. AvevoRx's nursing program saw a 70 percent year-over-year increase in visits in 2025, while the company doubled its nursing staff over two years to more than 200 field clinicians. These investments have helped AvevoRx evolve from a Greensboro-based startup into a national specialty infusion pharmacy platform, enabling the company to serve more patients, support more providers, and expand access to high-quality specialty therapies while maintaining its emphasis on high-touch, personalized care.

The Triad Fast 50 recognizes 50 of the region's fastest-growing privately held companies, and the 2026 program celebrated companies demonstrating significant growth, entrepreneurship, and business success across the Greensboro-Winston-Salem-High Point region. AvevoRx's Fast 50 recognition caps a year of continued expansion for the company, which has seen major developments in virtually every dimension of its national platform.